Health Committee tries to cut through contradictions and confusion over reforms to drug prices regulator
At the core of the issue is ‘two ways to perceive the role' of the Patented Medicines Prices Review Board, says an Ottawa University health policy professor.
Recent testimony at the House Health Committee by the health minister and former members of an organization that regulates drug prices in Canada has left members grappling with “two thoroughly contradictory versions of events,” says NDP MP Don Davies.
SPONSORED CONTENT
Get Today’s Headlines Newsletter
Your quick scan of the news you need each weekday to be the smartest person in the room.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
